INBS

Intelligent Bio Solutions is a pre-scale medical-technology micro-cap whose numbers describe a liquidity emergency, not a growth story. FY2025 revenue was $3.05M and actually shrank 1.9% YoY, while the company lost $10.6M — an operating margin of -348.7% and a net margin of -346.2%. The five-year revenue history ($1.98M → $437K → $1.26M → $3.11M → $3.05M) shows no durable, compounding trajectory, just volatility around a tiny base. Gross profit fell 12.5% even as the top line held flat, so unit economics are moving the wrong way (gross margin 40.8%). This is a company that spends roughly $3.50 to generate $1.00 of sales.

The balance sheet is the disqualifier. Cash fell 83.8% to just $1.02M against operating cash burn of $9.68M — barely five to six weeks of runway at the current rate. Current liabilities ($5.35M) exceed current assets ($4.14M), so working capital is already negative. Total assets dropped 40.1% and stockholders' equity collapsed 64% to $3.00M against $5.44M of liabilities (1.81x leverage), with an accumulated deficit of -$62.5M. Management says so itself: the 10-K flags 'substantial doubt about the Company's ability to continue as a going concern unless it can successfully raise additional capital,' and separately warns it 'may not be able to repay the grant it received from the Australian Government on time.' Shares outstanding already jumped 111.3% in a year — existing holders have been heavily diluted, and the only visible path to survival is more of the same, on whatever terms are available 'or at all.'